|
Agenda
|
Financial Highlights of FY2082/83, Appointment of Auditors for the FY2083/84, Election of Directors from Promoter Shareholders, Acquire Royal Pharmaceuticals Limited, Memorandum of Understanding (MOU), Amendments, Establishment of Acquisition Committee, Appointment of Independent Valuator/Legal Advisor, Due Diligence Audit Report (DDAR), Scheme of Arrangement, Share Ratio (1:0.5744), Amendment on Articles/Memorandum, Authority to the Board of Directors, Book Closure and Miscellaneous. |